Acta Pharmaceutica Sinica B
|
2026, 16(4): 2587-2592
• Letter to the Editor •
Identification of HMGB1 as a target of 3-O-benzoyl-20-deoxyingenol in NSCLC therapy using integrated ABPP and SIP
Full
Yaxu Wang1,2, Yan Liu1, Yuan Zhuang1,2, Wennan Luo2, Lu Pan1,2, Liwei Gu2, Jigang Wang1,2, Qingbo Liu1, Shao-Jiang Song1
Affiliations
1 Key Laboratory of Computational Chemistry Based Natural Antitumor Drug Research & Development, Liaoning Province, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China;
2 State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
doi: 10.1016/j.apsb.2026.01.043
Outline
NSCLC
/
3-O-Benzoyl-20-deoxyingenol
/
HMGB1
/
Autophagy-mediated apoptosis
/
Immunogenic cell death
Yaxu Wang, Yan Liu, Yuan Zhuang, Wennan Luo, Lu Pan, Liwei Gu, Jigang Wang, Qingbo Liu, Shao-Jiang Song.
Identification of HMGB1 as a target of 3-O-benzoyl-20-deoxyingenol in NSCLC therapy using integrated ABPP and SIP[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(4)
: 2587
-2592
.
DOI: 10.1016/j.apsb.2026.01.043
Year 2026 volume 16 Issue 4
PDF
8
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.01.043
- Receive Date:2025-08-11
- Online Date:2026-09-17